Fig. 6: Effective tumor therapy by silencing EGFR in A549ACE2+ tumors with siEGFR@eS-BNVs.
a Scheme shows in vivo tumor therapy by i.v. administration of siEGFR@eS-BNVs to A549ACE2+ tumor-bearing mice on days 10, 12, 14, 16 and 18, and then injected with Thr enzyme by i.v. injection (1.5 U per mouse) at 12 h after drug administration. Created in BioRender. Cui, L. (2025) https://BioRender.com/umqxomy. b, c Average tumor growth rates (b) and individual tumor growth rate (c) of A549ACE2+ tumors after treating by siEGFR@eS-BNVs + Thr (n = 6 independent samples). d Survival rates of A549ACE2+ tumor-bearing mice after treating by siEGFR@eS-BNVs + Thr and control samples. e Western blot and statistically analyzing the EGFP receptor expressed in A549ACE2+ tumors were tested on day 16 (n = 6 independent samples). fEGFR mRNA levels expressed in the A549ACE2+ tumors as tested on day 16 (n = 6 independent samples). g Immunofluorescent staining of EGFR expressed in the A549ACE2+ tumors after the above treatments. Red, EGFR stained by anti-EGFR antibody; blue, nucleus stained by DAPI. Scale bars, 500 μm. Experiment in (g) was repeated three times independently with similar results. Data in (b, e and f) are the mean ± s.d. p-values were determined by two-tailed Student’s t test in (b) or one-way ANOVA test in (e, f). ****p < 0.0001, ***p < 0.001, *p < 0.05. Source data are provided in a Source Data file.
